Upgrade to SI Premium - Free Trial

ACHFF (ACHFF)

0.60 0.00 (0.00%)

Chart
Today 6M 1Y 5Y

Latest Headlines

Arch Biopartners Engages Private Laboratory to Accelerate IL-32 Chronic Kidney Disease Program July 17, 2026 8:20 AM - Globe NewsWire Arch Biopartners Featured in American Diabetes Association Thought Leadership Series at the 2026 Scientific Sessions in New Orleans June 4, 2026 7:41 AM - Globe NewsWire Arch Biopartners announces Royal Columbian Hospital has dosed its first patient in its Phase II cardiac surgery-associated AKI trial May 22, 2026 6:50 AM - Globe NewsWire Royal Columbian Hospital begins patient recruitment in Arch Biopartners’ Phase II trial of LSALT peptide targeting CS-AKI April 30, 2026 7:00 AM - Globe NewsWire Full Article List